UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 552

Sortiert nach

PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis

Cell, 2012-08, Vol.150 (4), p.685-696

2012

Volltextzugriff (PDF)

Molecular Mechanisms of Treatment Resistance in Glioblastoma

International journal of molecular sciences, 2020-12, Vol.22 (1), p.351

2020

Volltextzugriff (PDF)

Role of AKT signaling in DNA repair and clinical response to cancer therapy

Neuro-oncology (Charlottesville, Va.), 2014-10, Vol.16 (10), p.1313-1323

2014

Volltextzugriff (PDF)

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1419-1427

2018

Volltextzugriff (PDF)

Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation

Nature communications, 2021-01, Vol.12 (1), p.139-11, Article 139

2021

Volltextzugriff (PDF)

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4733-4740

2009

Volltextzugriff (PDF)

FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis

Cancer cell, 2011-10, Vol.20 (4), p.427-442

2011

Volltextzugriff (PDF)

Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers

Oncotarget, 2014-09, Vol.5 (18), p.8202-8210

2014

Volltextzugriff (PDF)

Antitumor Activity of NVP-BKM120―A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

Clinical cancer research, 2012-01, Vol.18 (1), p.184-195

2012

Volltextzugriff (PDF)

Current clinical development of PI3K pathway inhibitors in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.819-829

2012

Volltextzugriff (PDF)

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma

Acta neuropathologica, 2015-10, Vol.130 (4), p.587-597

2015

Volltextzugriff (PDF)

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Clinical cancer research, 2018-02, Vol.24 (4), p.737-743

2018

Volltextzugriff (PDF)

Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution

Journal of neuro-oncology, 2014-12, Vol.120 (3), p.597-605

2014

Volltextzugriff (PDF)

Pathway inhibition: emerging molecular targets for treating glioblastoma

Neuro-oncology (Charlottesville, Va.), 2011-06, Vol.13 (6), p.566-579

2011

Volltextzugriff (PDF)

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

Clinical cancer research, 2020-03, Vol.26 (6), p.1395-1407

2020

Volltextzugriff (PDF)

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2204-2210

2009

Volltextzugriff (PDF)

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model

PloS one, 2014-05, Vol.9 (5), p.e97407-e97407

2014

Volltextzugriff (PDF)

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice

Clinical cancer research, 2015-10, Vol.21 (20), p.4630-4641

2015

Volltextzugriff (PDF)

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (19), p.5088-5101

2019

Volltextzugriff (PDF)

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2689-2695

2011

Volltextzugriff (PDF)

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

Journal of neuro-oncology, 2017-03, Vol.132 (1), p.181-188

2017

Volltextzugriff (PDF)

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Journal of clinical oncology, 2019-03, Vol.37 (9), p.741-750

2019

Volltextzugriff (PDF)

Moving toward molecular classification of diffuse gliomas in adults

Neurology, 2012-10, Vol.79 (18), p.1917

2012

Volltextzugriff (PDF)

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03

Neuro-oncology (Charlottesville, Va.), 2011-05, Vol.13 (5), p.509-516

2011

Volltextzugriff (PDF)

1 – 25 von 552

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(516)
Mit Volltextzugriff
(519)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neuro-Oncology
(144)
Journal Of Clinical Oncology
(46)
Cancer Research
(39)
Journal Of Neuro-Oncology
(36)
Clinical Cancer Research
(21)
Oncogene
(10)
Neoplasia
(8)
Neurosurgery
(8)
Jnci : Journal Of The National Cancer Institute
(7)
Molecular Cancer Therapeutics
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis

Molecular Mechanisms of Treatment Resistance in Glioblastoma

Role of AKT signaling in DNA repair and clinical response to cancer therapy

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma

Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis

Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers

Antitumor Activity of NVP-BKM120―A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

Current clinical development of PI3K pathway inhibitors in glioblastoma

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution

Pathway inhibition: emerging molecular targets for treating glioblastoma

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Moving toward molecular classification of diffuse gliomas in adults

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03

Suchergebnisse filtern